Protocol Ledger

NCT03896074 · Phase II · ACTIVE NOT RECRUITING

Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)

Interventional Phase II clinical trial protocol NCT03896074 sponsored by Fondazione Ricerca Traslazionale in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-03-02 Enrollment: 206 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03896074
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)206 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03896074
Protocol FieldVerified Registry Value
NCT IdentifierNCT03896074
Consolidated Lead SponsorFondazione Ricerca Traslazionale
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment206 participants (ESTIMATED)
Registered Start Date2020-03-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03896074
Hospital Research SiteLocationSite Profile
Fondazione IRCCS CA' Granda Ospedale Maggiore PoliclinicoMilan, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI